CRON Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 1.6%, SMA50 -0.72%, SMA200 10.39%). The stock’s 14-day RSI is 51.08 (neutral), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.16% below its high and over 66.88% above its low. Average 10-day trading volume of 816.21 thousand shares is below the 3-month average of 1.15 million, indicating normal recent market interest.

Cronos Group Inc. generated EPS of $0.09 over the past year. Five-year average earnings growth is -50.98%. Wall Street analysts project EPS growth of 2.94% annually over the next five years. The latest quarter delivered EPS of $0.08. The next quarter is forecast at $0.02. Next year's EPS is expected at $52.94. Cronos Group Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 733.0%. The prior quarter beat by 300.0%. Over the last six quarters, Apple has recorded several small beats. These include -378.55% in May 08, 2025.

Cronos Group Inc. has 368.41 million shares outstanding. The public float is 186.99 million shares, elevated short interest at 1.78% of float. This equals 3.24 million shares. The short ratio is 1.94 days. Institutional investors hold 30.31% of the float. Insiders own 48.55%. GORENSTEIN MICHAEL RYAN holds 8.43 million shares, ADLER JASON MARC has 601.02 thousand shares and ABRAHAM TODD KEVIN has 15.00 thousand shares.

Cronos Group Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.64. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $2.28 and $3.61. With a market capitalization of about $1.18 billion, Cronos Group Inc. is classified as a small-cap and shows market-like volatility (beta ~1.28). Key stats such as the average daily volume over the past year has been around 1.16 million shares, volume is running light vs its 52-week average. Headquartered in Stayner, ON, Cronos Group Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Michael Ryan Gorenstein, the company employs approximately 610 people and listed since February 27, 2018. Cronos Group Inc. is a company primarily focused on cannabinoids.

Cronos Group Inc. trades at a P/E ratio of 17.37, slightly below the S&P 500 average, with a price-to-sales ratio of 4.85 and a price-to-book ratio of 1.14 suggesting the stock is closer to book value. The P/FCF stands at 26.42, also above market averages.

Our AI price prediction model suggests that Cronos Group Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.43%, with price expected at $3.02 by September 24, 2026, within a range of $2.91 to $3.14 3-Month Outlook: Projected rise of 5.06%, reaching $3.32 by December 09, 2026, with a range of $3.28 to $3.35. 1-Year Outlook: Projected gain of 681.65%, with price at $24.70 by September 10, 2027, within a range of $24.71 to $27.36.

Cronos Group Inc. (NASDAQ:CRON) shares are flat -3.04% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cronos Group Inc. trading at a premium to the broader market with a P/E of 17.37. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $5.39, suggesting 70.57% upside. Our AI forecast model points to short-term weakness (-4.43% over two weeks), a medium-term rise (5.06% over three months), and a longer-term gain (681.65% over one year), with expected trading ranges indicating moderate volatility.